Table of Contents Author Guidelines Submit a Manuscript
Review Article
Oxidative Medicine and Cellular Longevity
Volume 2018, Article ID 1897257, 2 pages
https://doi.org/10.1155/2018/1897257
Corrigendum

Corrigendum to “The Utility of Ovotransferrin and Ovotransferrin-Derived Peptides as Possible Candidates in the Clinical Treatment of Cardiovascular Diseases”

1College of Bioscience and Biotechnology and College of Animal Science and Technology, Hunan Agricultural University, Changsha 410128, China
2Hunan Province University Key Laboratory for Agricultural Biochemistry and Biotransformation, Hunan Agricultural University, Changsha 410128, China
3Hunan Co-Innovation Center for Utilization of Botanical Functional Ingredients, Changsha 410128, China

Correspondence should be addressed to Xiaosong Wu; moc.621@1370gnosoaixuw and Jun Fang; nc.ude.uanuh@3791nujgnaf

Received 27 September 2018; Accepted 2 October 2018; Published 13 December 2018

Copyright © 2018 Shuang Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


In the article titled “The Utility of Ovotransferrin and Ovotransferrin-Derived Peptides as Possible Candidates in the Clinical Treatment of Cardiovascular Diseases” [1], there is a missing section that should be added between sections 4 and 5 as follows:

5. Research on Ovotransferrin or Ovotransferrin-Derived Peptides in Cardiovascular Disease

Due to the rapid development of biomedicine, many nonconquerable diseases have been alleviated and treated in varying degrees. But inevitably, synthetic drugs have side effects, and there is a strong interest in finding new bioactive substances as potential candidates for treatment. Bioactive peptides exert systemic effects by entering the circulation via the intestinal tract or produce local effects in the gastrointestinal tract. But the most important thing is that it enhances health and safety profiles and may be a candidate for cardiovascular disease treatment [49]. The causes of cardiovascular disease are diverse, such as lifestyle habits, eating habits, and many congenital causes, which plague people’s normal life. Studies have shown that ovotransferrin and ovotransferrin-derived peptides could be anti-inflammatory, anti-oxidatory, and inhibit ACE to ease the development of cardiovascular disease (Table 1). Tumor necrosis factor (TNF) is a proinflammatory cytokine, which plays an important role in the development of atherosclerosis. TNF can upregulate the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in endothelial cells, leading to the development and progression of vascular inflammation. Studies have shown that ovalbumin-ovotransferrin peptides (IRW and IQW) could alleviate TNF-induced inflammation and oxidative stress in endothelial cells [43]. RVPSL, a bioactive peptide from egg protein, was found to reduce the blood pressure of spontaneous hypertensive rats and reduce the mRNA expression of renin, ACE, and AT1 receptor in the kidney. In addition, the concentrations of angiotensin II, renin, and aldosterone in serum dropped. This indicated that RVPSL has the potential to treat hypertension [50]. So far, no human-targeted clinical trials of ovotransferrin or ovotransferrin-derived peptides have been carried out, though that does not negate its therapeutic potential. Bioactive peptides from other sources have been studied in hypertensive patients. For example, VPP, an active peptide in fermented milk, has been shown to reduce blood pressure in hypertensive patients [51].

Table 1: The regulators of ovotransferrin and ovotransferrin-derived peptides and adjusting effect.

In addition, the following references should have been included in the references list of the original article [1]: (i)Erdmann et al. [2] should be added as reference [49].(ii)Yu et al. [3] should be added as reference [50].(iii)Seppo et al. [4] should be added as reference [51].(iv)Liao et al. [5] should be added as reference [52].(v)Huang et al. [6] should be added as reference [53].

References

  1. S. Chen, H. Jiang, H. Peng, X. Wu, and J. Fang, “The utility of ovotransferrin and ovotransferrin-derived peptides as possible candidates in the clinical treatment of cardiovascular diseases,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 6504518, 6 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Erdmann, B. W. Y. Cheung, and H. Schröder, “The possible roles of food-derived bioactive peptides in reducing the risk of cardiovascular disease,” The Journal of Nutritional Biochemistry, vol. 19, no. 10, pp. 643–654, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Yu, Y. Yin, W. Zhao, F. Chen, and J. Liu, “Antihypertensive effect of angiotensin-converting enzyme inhibitory peptide RVPSL on spontaneously hypertensive rats by regulating gene expression of the renin-angiotensin system,” Journal of Agricultural and Food Chemistry, vol. 62, no. 4, pp. 912–917, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Seppo, T. Jauhiainen, T. Poussa, and R. Korpela, “A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects,” The American Journal of Clinical Nutrition, vol. 77, no. 2, pp. 326–330, 2003. View at Publisher · View at Google Scholar
  5. W. Liao, H. Fan, and J. Wu, “Egg white-derived antihypertensive peptide IRW (Ile-Arg-Trp) inhibits angiotensin II-stimulated migration of vascular smooth muscle cells via angiotensin type I receptor,” Journal of Agricultural and Food Chemistry, vol. 66, no. 20, pp. 5133–5138, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. W.-Y. Huang, K. Majumder, and J. Wu, “Oxygen radical absorbance capacity of peptides from egg white protein ovotransferrin and their interaction with phytochemicals,” Food Chemistry, vol. 123, no. 3, pp. 635–641, 2010. View at Publisher · View at Google Scholar · View at Scopus